Abstract
The aim of this review is to evaluate the use of chemotherapy (CT) in the treatment of squamous vulvar cancer. Since the 90s there was a continuous evolution in the therapeutic approach to this tumour. Although primary surgery is now considered the most effective approach, there are advanced diseases in which surgery may compromise anatomical structures causing severe mutilation. These are the reasons why CHT, with or without concomitant radiotherapy RT, started to be strongly recommended as neoadjuvant strategy. Chemotherapeutic agents have also been used alone as adjuvant treatment or in association with RT, by exploiting the radiosensitizing effect of these drugs. There are few data about the use of CHT as palliative treatment but recent studies point to the use of target therapy. In conclusion, clinical data and the evidence of chemo-sensitivity in vulvar squamous cell carcinoma open new possibilities to future research in this field.
| Original language | English |
|---|---|
| Pages (from-to) | 25-39 |
| Number of pages | 15 |
| Journal | Critical Reviews in Oncology/Hematology |
| Volume | 82 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Apr 2012 |
Fingerprint
Keywords
- Chemotherapy
- Squamous vulvar cancer
ASJC Scopus subject areas
- Oncology
- Hematology
- Geriatrics and Gerontology
Cite this
Role of chemotherapy in the management of vulvar carcinoma. / Tomao, Federica; Di Tucci, Chiara; Marchetti, Claudia; Perniola, Giorgia; Bellati, Filippo; Panici, Pierluigi Benedetti.
In: Critical Reviews in Oncology/Hematology, Vol. 82, No. 1, 04.2012, p. 25-39.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Role of chemotherapy in the management of vulvar carcinoma
AU - Tomao, Federica
AU - Di Tucci, Chiara
AU - Marchetti, Claudia
AU - Perniola, Giorgia
AU - Bellati, Filippo
AU - Panici, Pierluigi Benedetti
PY - 2012/4
Y1 - 2012/4
N2 - The aim of this review is to evaluate the use of chemotherapy (CT) in the treatment of squamous vulvar cancer. Since the 90s there was a continuous evolution in the therapeutic approach to this tumour. Although primary surgery is now considered the most effective approach, there are advanced diseases in which surgery may compromise anatomical structures causing severe mutilation. These are the reasons why CHT, with or without concomitant radiotherapy RT, started to be strongly recommended as neoadjuvant strategy. Chemotherapeutic agents have also been used alone as adjuvant treatment or in association with RT, by exploiting the radiosensitizing effect of these drugs. There are few data about the use of CHT as palliative treatment but recent studies point to the use of target therapy. In conclusion, clinical data and the evidence of chemo-sensitivity in vulvar squamous cell carcinoma open new possibilities to future research in this field.
AB - The aim of this review is to evaluate the use of chemotherapy (CT) in the treatment of squamous vulvar cancer. Since the 90s there was a continuous evolution in the therapeutic approach to this tumour. Although primary surgery is now considered the most effective approach, there are advanced diseases in which surgery may compromise anatomical structures causing severe mutilation. These are the reasons why CHT, with or without concomitant radiotherapy RT, started to be strongly recommended as neoadjuvant strategy. Chemotherapeutic agents have also been used alone as adjuvant treatment or in association with RT, by exploiting the radiosensitizing effect of these drugs. There are few data about the use of CHT as palliative treatment but recent studies point to the use of target therapy. In conclusion, clinical data and the evidence of chemo-sensitivity in vulvar squamous cell carcinoma open new possibilities to future research in this field.
KW - Chemotherapy
KW - Squamous vulvar cancer
UR - http://www.scopus.com/inward/record.url?scp=84858761517&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858761517&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2011.04.008
DO - 10.1016/j.critrevonc.2011.04.008
M3 - Article
VL - 82
SP - 25
EP - 39
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
IS - 1
ER -